The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | The safety and efficacy of selinexor for the treatment of myeloma
In this video, Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the safety and efficacy of selinexor for the treatment of multiple myeloma. Dr Cerchione first mentions the impressive data observed in the STORM trial (NCT02336815) and the BOSTON trial (NCT03110562), as well as the promise of selinexor as a single agent. Dr Cerchione also comments on the improved management and understanding of adverse events, and concludes by highlighting the promise of the EMN29 trial (NCT05028348) investigating the combination of selinexor, pomalidomide, and dexamethasone (SPd) in patients with previously treated myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
